LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.

Transl Neurodegener · 2024 · PMC10910783 · PMID 38438877

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

Overall, wild-type and LRRK2 G2019S microglia had similar cell body size and Iba-1 intensity, with a slight trend to lower cell body size and higher Iba-1 intensity in the 450 mg/kg MLi-2-treated animals (Additional file 1 : Fig.

also in 1,866 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.